^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    cergutuzumab amunaleukin (RG7813)

    i
    Associations
    News

    Trials

    Company:
    Roche
    Drug class:
    Immunostimulant, IL-2 stimulant, CEACAM5 inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors (NCT02350673)
    Phase 1b
    Hoffmann-La Roche
    Completed
    Last update posted :
    01/18/2020
    Initiation :
    06/29/2015
    Primary completion :
    12/16/2019
    Completion :
    12/16/2019
    CD8 • CEACAM5
    |
    CEACAM5 expression
    |
    Tecentriq (atezolizumab) • cergutuzumab amunaleukin (RG7813)
    A Study to Evaluate Safety, Pharmacokinetics, and Efficacy of RO6895882 in Participants With Advanced and/or Metastatic Solid Tumors (NCT02004106)
    Phase 1
    Hoffmann-La Roche
    Completed
    Last update posted :
    03/06/2018
    Initiation :
    12/31/2013
    Primary completion :
    08/31/2016
    Completion :
    08/31/2016
    CD8 • CEACAM5
    |
    CEACAM5 expression
    |
    cergutuzumab amunaleukin (RG7813)